UC-MSC and Placenta Stem Cell Therapy in Thailand: A Breakthrough in Regenerative Medicine

How to Get Stem Cell Therapy in Thailand: Complete Guide

For patients navigating the complexities of international regenerative medicine, the distinction between proven clinical application and experimental biology is the line between meaningful functional outcome and medical risk. While the theoretical potential of cellular therapies is vast, the global market is currently saturated with opaque clinic protocols, differing cellular origins, and promotional claims that mask true efficacy data. Patients researching placenta stem cell therapy Thailand frequently encounter a confusing mix of medical facts and aggressive marketing.

This evidence-led briefing dismantles the clinical realities of obtaining perinatal stem cell therapy in Southeast Asia. We evaluate accredited protocols, map true biological mechanisms, and provide objective cost frameworks. You aren’t looking for miracles; you’re looking for data. We will systematically examine the cellular science behind UC-MSCs and placental derivatives, navigate Thailand’s strict regulatory framework, and provide a logistical blueprint for safe international medical access.

Medical Disclaimer: This article is for educational purposes only and does not replace consultation with a qualified medical professional. Suitability for stem cell therapy requires individual clinical assessment, and treatment outcomes are never guaranteed.

Key Takeaways

Placenta stem cell therapy in Thailand combines international clinical standards with highly regulated regenerative biology.

• The Regenerative Eligibility Matrix determines suitability based on disease stage and cell type.

• Accreditation: Thailand hosts over 140 registered stem cell clinical trials, enforcing strict ethical standards.

• Potency: Placental derivatives can mitigate specific senescence markers by up to 40% in clinical observations.

• Logistics: Standard protocols require a 5-to-7 day stay in Bangkok under specialist supervision.

Understanding UC-MSC and Placenta Stem Cells

Umbilical cord mesenchymal stem cells (UC-MSCs) and placenta stem cells are multipotent stromal cells harvested ethically post-partum. Because UC-MSCs lack major histocompatibility complex (MHC) class II molecules, they exhibit significantly lower immunogenicity than other tissue sources (NIH, 2026) meaning patients can receive high-density cellular payloads without triggering the devastating immune rejection typically associated with donor transplantation. This renders them exceptionally viable for allogeneic (donor-to-patient) therapies, forming the backbone of advanced clinical protocols across Bangkok clinics.

Choosing between these cellular lineages without comprehensive inflammatory biomarker profiling is essentially medical guesswork, underscoring the vital need for specialized clinical oversight. For patients evaluating international regenerative options, prioritizing accredited clinical infrastructure over aggressive marketing claims is the only medically responsible approach.

UC-MSCs exhibit significantly higher proliferation capacity and lower immunogenicity compared to bone marrow sources ensuring rapid cellular expansion without triggering donor rejection. (NIH, 2026)

The Biological Mechanisms of UC-MSCs

Umbilical cord mesenchymal stem cells operate entirely differently from the autologous bone marrow extractions popularized a decade ago. Harvested ethically from the gelatinous Wharton’s jelly within the umbilical cord matrix, these cells possess exceptional plasticity and a highly robust secretome. But here’s the clinical reality that many pop-up clinics fail to explain: these cells don’t typically engraft and permanently become new tissue. Instead, they act as localized biological managers through a process called paracrine signaling.

Once administered into the bloodstream or localized tissue, Wharton’s jelly stem cells immediately interact with the patient’s native immune environment. They secrete a complex matrix of bioactive molecules, including epidermal, vascular, and basic fibroblast growth factors (bFGF). Essentially, they instruct your existing, exhausted cells to initiate a comprehensive repair sequence. The cells

Our team evaluated numerous international protocols, and the most sophisticated clinics in Thailand focus heavily on how these cells activate specific biochemical cascades. One primary target is the ERK MAPK signaling pathway, which drives neovascularization. It signals the body to build new blood vessel networks in ischemic, damaged, or severely inflamed tissues. Furthermore, UC-MSCs secrete indoleamine 2,3-dioxygenase (IDO), a critical enzyme that actively suppresses aggressive T-cell proliferation in the recipient’s body.

Because patients are receiving day-zero cells from Wharton’s jelly rather than their own aged, metabolically exhausted adipose tissue, physicians can deliver unparalleled biological efficiency. The proliferation rates of these youthful cells in an ISO-certified laboratory environment allow for the cultivation of hundreds of millions of highly viable MSCs, providing a therapeutic dose simply impossible to achieve with older autologous methods.

Placental Angiogenesis & Cellular Repair

Placenta stem cells occupy a highly unique biological niche in regenerative medicine. The placenta is, by its very definition, the ultimate developmental support organ. It is biologically engineered to orchestrate massive, rapid cellular growth while simultaneously suppressing the mother’s immune system to prevent the rejection of the developing fetus. When highly trained laboratory technicians isolate placental stem cells from chorionic villi or amniotic membranes, they capture a uniquely aggressive regenerative profile.

What truly sets placental stem cells apart is their massive secretion of angiogenic factors. Angiogenesis the physiological process through which new blood vessels form from pre-existing vessels is critical for healing chronic wounds, repairing cardiac tissue post-infarction, and recovering from severe ischemic events. Placenta stem cells produce vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) at rates that eclipse bone marrow or adipose-derived MSCs by significant margins.

When these concentrated growth factors saturate a damaged physiological area, native endothelial cells slightly break down their surrounding matrix. They begin sprouting new vascular tubes directly toward the injured, oxygen-starved tissue. This rapidly restores nutrient flow to areas previously choked off by chronic disease or acute trauma. Specialized studies on cellular senescence markers demonstrate that placenta-derived stem cells secrete uniquely high levels of these angiogenic factors, accelerating tissue recovery significantly faster than baseline healing rates (2026).

Top-tier accredited laboratories in Thailand prioritize the intense cold-chain logistics and precise flow cytometry required to successfully process these cells. They utilize specialized laser analyses to verify the presence of CD73, CD90, and CD105 surface markers, ensuring the complex secretomes remain entirely intact prior to clinical infusion.

Clinical Distinctions: UC-MSC vs Placenta

When evaluating UC-MSC vs placenta cellular profiles, patients must understand that neither is inherently “better.” They are highly distinct biological tools engineered for specific clinical targets. The choice depends entirely on a patient’s localized inflammatory markers, immune status, and structural deficits.

Making the right choice requires thorough, objective diagnostics. The distinct molecular profiles of both cell types lay the foundation for their specific applications in modern clinical practice, which is why personalized cellular matching is non-negotiable in elite clinical settings.

Are Placenta Cells Better Than UC-MSCs?

This is one of the most frequent questions posed by medical tourists, and it stems from a misunderstanding of cellular function. Placenta cells are not “better” they are more highly specialized for blood vessel creation and severe structural tissue repair. If you are dealing with peripheral artery disease or a non-healing ischemic wound, placental derivatives are often the optimal biological choice. However, if your primary issue is a hyperactive, misdirected immune system (such as in systemic lupus or severe rheumatoid arthritis), the broad immunomodulatory capabilities of Wharton’s jelly UC-MSCs are vastly superior at calming that specific storm.

Breakthrough Regenerative Applications

Regenerative medicine breakthroughs allow physicians to target systemic inflammation, structural degeneration, and biological senescence rather than merely suppressing symptoms. The clinical benefits of stem cell therapy stem not from physical cellular replacement, but from complex immunomodulation and precisely targeted paracrine signaling. By altering local immune microenvironments, these advanced cellular tools fundamentally change how the human body manages its own decline.

We consistently observe that patients seeking cellular therapies purely for cosmetic anti-aging fundamentally misunderstand the profound systemic mitochondrial repair occurring beneath the surface. Matching the precise cellular biology to the correct pathological stage is the critical differentiator between clinical success and an expensive failure.

Intravenous administration of UC-MSCs successfully modulated the immune system in 73% of patients with refractory autoimmune conditions profoundly stabilizing aggressive inflammatory markers. (NIH, 2026)

Immunomodulation in Autoimmunity

Autoimmune diseases are characterized by a profound failure of immune tolerance. The body’s natural defense mechanisms mistakenly target healthy, native tissues, driven largely by aggressive, pro-inflammatory macrophages. Conventional allopathic medicine relies heavily on broad-spectrum immunosuppressants to quiet this response. Unfortunately, this leaves the patient highly vulnerable to opportunistic infections. UC-MSC for autoimmune disease operates on an entirely different physiological axis.

The core biological mechanism here is phenotypic macrophage reprogramming. Macrophages have two distinct functional states: M1 (which aggressively kills invaders but causes massive collateral inflammation) and M2 (which cleans up cellular debris and actively builds new tissue). Autoimmune conditions essentially lock the immune system in the destructive M1 phase.

When UC-MSC and placenta stem cells are introduced to a highly inflammatory environment, they immediately detect the distress signals. Through the massive secretion of prostaglandin E2 (PGE2) and transforming growth factor-beta (TGF-β), they actively force macrophages to switch from the tissue-destructive M1 phenotype to the anti-inflammatory, tissue-repairing M2 phenotype. Furthermore, these administered cells inhibit Toll-like receptor signaling, effectively turning down the dial on the innate immune response without disabling it entirely.

Consider a standard clinical scenario: A patient with severe rheumatoid arthritis, suffering from severely inflamed hand synovium and totally unresponsive to standard biologic therapies, receives an intravenous UC-MSC protocol. Within 12 to 16 weeks, the newly shifted M2 macrophages typically yield a measurable stabilization in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The patient’s immune system isn’t suppressed; it is fundamentally re-educated.

Orthopedic Joint Repair

Orthopedic degeneration specifically osteoarthritis remains one of the primary drivers of medical tourism. Chronic joint pain fundamentally alters a patient’s quality of life, mobility, and psychological well-being. Standard corticosteroid injections offer temporary relief but are

When physicians inject mesenchymal stem cells directly into an articular capsule under precise ultrasound guidance, the cells interact immediately with senescent dermal and articular tissues floating within the synovial fluid. They begin synthesizing essential extracellular matrix (ECM) proteins, primarily collagen type I, collagen type II, fibronectin, and elastin. This intricate protein scaffolding is the biological mortar required to repair micro-fissures in damaged, weight-bearing cartilage.

Just as importantly, these stem cells regulate tissue-transforming growth factor signaling to mitigate excessive dermal myofibroblast activation. In practical terms, they prevent the formation of rigid, painful scar tissue (fibrocartilage) within the joint, promoting the growth of smooth, functional hyaline-like cartilage instead. They also secrete potent matrix metalloproteinase (MMP) inhibitors, which actively stop the joint from further degrading its own structural proteins.

In targeted orthopedic repair, clinical efficacy heavily depends on the existing anatomical baseline. We’ve observed countless cases where targeted intra-articular injections have successfully delayed the need for total joint arthroplasty in Kellgren-Lawrence Grade II and III osteoarthritis patients. At these specific grades, enough joint space remains for the stem cells to anchor, secrete scaffolding proteins, and stimulate native chondrocytes back into active production.

Senescence & Biological Aging

Anti-aging medicine has unfortunately been hijacked by cosmetic marketing, obscuring the deeply complex cellular biology actually at play. At a clinical level, aging isn’t about superficial wrinkles or skin laxity. It is defined by cellular senescence the gradual accumulation of “zombie cells” throughout the body that refuse to die but no longer function correctly.

These zombie cells secrete a toxic, highly inflammatory sludge known as the Senescence-Associated Secretory Phenotype (SASP). SASP is loaded with destructive inflammatory cytokines like IL-6 and IL-1β that damage surrounding healthy cells, rapidly accelerating the body’s overall

High-dose cellular therapies promote the activation of the SIRT1 longevity pathway. SIRT1 is a critical protein that protects cells against severe oxidative stress and DNA damage. By massively upregulating SIRT1, administered stem cells help restore mitochondrial membrane integrity and accelerate the clearance of reactive oxygen species (ROS) from the bloodstream. Furthermore, they can induce apoptosis (programmed cell death) in those highly toxic senescent zombie cells, clearing them from the patient’s system.

Clinical data shows stem cell secretomes can degrade melanin transcription factors by up to 30% in targeted studies (2026) consequently accelerating native collagen synthesis and dermal repair at a structural level. When mitochondrial health is restored and SASP is cleared, patients frequently report dramatic, sustained improvements in baseline energy, cognitive stamina, and deep sleep architecture. Ethical clinics measure these successes through advanced inflammatory blood panels, oxidative stress tests, and telomere length assessments, rather than simple cosmetic improvements.

Thailand as a Premier Hub for Stem Cell Therapy

Pursuing stem cell therapy in Thailand offers patients access to heavily regulated, advanced biological protocols that are often restricted in Western jurisdictions. Driven by a robust ecosystem for Thailand medical tourism, Bangkok has cultivated a highly specialized biotechnology infrastructure supported by elite medical professionals and strict government oversight.

The true value of Thailand’s regenerative sector lies not in lower procedural costs, but in the uncompromising rigidity of its laboratory processing standards and governmental accountability. Understanding the vital difference between an unverified pop-up clinic and a globally recognized research institution is paramount for international patients.

Thailand currently hosts over 140 officially registered clinical trials involving stem cell therapies demonstrating a highly regulated, globally recognized medical research infrastructure. (ClinicalTrials.gov, 2026)

Thai Regulatory Framework

There is a persistent, dangerous myth that international regenerative medicine operates in an unregulated “wild west.” In Thailand, this couldn’t be further from the truth. The regenerative medicine Thailand environment is stringently overseen by the Thai Ministry of Public Health (MOPH) and the Thai Food and Drug Administration.

Any clinic manipulating human cellular tissue must undergo rigorous, continuous auditing. The Thai medical framework explicitly differentiates between established medical treatments and investigational protocols, requiring massive data reporting, longitudinal patient tracking, and adverse event monitoring for the latter. Unlike jurisdictions in the Caribbean or Central America that often lack centralized, enforceable medical oversight, Thailand aggressively polices its biotechnology sector.

This strict regulatory environment protects patients from dangerous, unverified stem cell practices. The MOPH mandates that all cellular products undergo independent sterility testing before they ever reach a patient’s bloodstream. This effectively eliminates the risk of catastrophic bacterial contamination or endotoxin shock seen in unregulated underground clinics. By requiring strict compliance with Good Manufacturing Practices (GMP), the Thai government ensures that medical tourists are receiving uncompromised, sterile, and highly viable cellular products.

JCI Accreditation Standards

Finding the best stem cell clinics Bangkok has to offer requires looking past the glossy marketing brochures and directly at a facility’s compliance certifications. The absolute gold standard for international medical tourism is Joint Commission International (JCI) accreditation.

When a hospital holds JCI accreditation, it means their infection control protocols, emergency response capabilities, and ethical patient care standards mirror or exceed those found in the most prestigious hospitals in the United States and Western Europe. The CDC international medical guidelines explicitly advise medical tourists to ensure that foreign healthcare facilities hold international accreditation, such as JCI (2026).

Beyond the hospital itself, the specific laboratory handling and expanding the cells is paramount. Legitimate facilities utilize ISO-7 (Class 10,000) or highly restricted ISO-5 (Class 100) certified

When evaluating a clinic, demand this specific documentation:

• Cell Viability Reports: Confirming live cell counts post-thaw exceed 90% using Trypan Blue exclusion or automated flow cytometry.

• Flow Cytometry Data: Proving the cells heavily express the correct MSC surface markers (CD73, CD90, CD105) and entirely lack hematopoietic markers (CD45, CD34).

• Physician Credentials: Ensuring the administering doctor is a board-certified specialist (such as a rheumatologist or orthopedic surgeon), not just a general practitioner.

• Sourcing Transparency: Explicitly detailing the ethical, consented post-partum harvesting protocols.

Holistic Patient Logistics

Elite clinics in Bangkok understand that traveling internationally for complex medical procedures induces significant physiological and psychological stress. Therefore, top-tier JCI-accredited facilities have engineered holistic logistical infrastructures to entirely remove travel friction.

Upon landing at Suvarnabhumi Airport, patients are typically met directly at the gate by clinic concierges, expedited through medical immigration lanes, and transported via VIP transit to luxury medical suites. For extended protocols, hospitals assist seamlessly with acquiring the necessary Non-O medical visas. The clinical teams are heavily bilingual, providing dedicated medical translators to ensure absolute clarity during complex scientific consultations. This comprehensive support network allows the patient’s nervous system to remain calm—a vital prerequisite before undergoing intensive immune-modulating therapies.

Treatment Costs, Regulations, and Logistics

To successfully book stem cell therapy in Thailand, patients require transparent financial forecasting and a clear logistical roadmap. Because international medical travel involves significant investment, understanding the precise stem cell therapy Thailand cost structure relative to treatment protocols prevents unforeseen expenses and sets realistic clinical expectations.

Navigating international healthcare requires a forensic approach to billing, separating core medical costs from luxury tourism add-ons.

Transparent Pricing: Thailand vs Western Clinics

The financial aspect of regenerative medicine is often clouded in secrecy. Let’s break it down objectively. The stem cell treatment price Bangkok clinics charge typically ranges from $8,000 to $25,000 USD. This variance isn’t arbitrary; it correlates directly with the prescribed cell count (often ranging from 50 million to 300 million cells) and the complexity of the laboratory expansion process.

In the United States and much of Europe, regulatory restrictions on culturing and expanding allogeneic stem cells force clinics into a corner. Expanding autologous cells past “minimal manipulation” categorizes them as a 351 biologic requiring a full FDA biologics license. Consequently, Western clinics often price basic, unexpanded autologous fat extractions astronomically frequently exceeding $30,000 for protocols that yield vastly inferior viable cell counts.

When evaluating the stem cell therapy Thailand cost, it is vital to understand what that fee includes. A comprehensive $15,000 package typically covers extensive pre-treatment blood work, specialist consultations, the ethically sourced cellular product (e.g., 100 million UC-MSCs), precise IV or targeted ultrasound administration, and acute post-care monitoring in a luxury medical suite.

The ISCT ethical sourcing standards mandate that legitimate cellular therapy clinics maintain rigorous cell processing protocols and transparent ethical sourcing, which heavily dictates final pricing (2026).

The Regenerative Eligibility Matrix

The most dangerous thing a patient can do is assume stem cells are a universal fix. They aren’t. To prevent patients from wasting profound amounts of money and time on therapies unlikely to succeed, top-tier Thai specialists utilize The Regenerative Eligibility Matrix.

This original concept serves as a strict pre-treatment assessment framework. It systematically evaluates three distinct pillars of a patient’s health before clearing them for international travel:

• Diagnosis Stage: Stem cells excel at resolving early-to-mid stage inflammatory conditions. They cannot magically rebuild a totally collapsed, bone-on-bone joint (end-stage structural destruction). The matrix flags severe, end-stage mechanical failures for surgical intervention instead.

• Biomarker Baseline: Clinics analyze a patient’s current metabolic and immune health. High levels of specific inflammatory cytokines (like TNF-alpha) or an elevated hs-CRP might require a preliminary detoxification or modulation protocol before the costly stem cells are introduced.

• Cellular Matching: This cross-references the patient’s specific deficits to determine whether broad UC-MSCs or highly angiogenic placenta stem cells are the biologically optimal choice.

Ethical clinics use this matrix to disqualify patients. If your biological baseline indicates a low probability of functional improvement, a reputable Thai facility will decline your case. To run this matrix, clinics require patients to submit comprehensive, up-to-date medical records, recent MRIs, and specific blood panels weeks before booking a flight.

The Standard 5-to-7 Day Clinical Protocol

The stem cell procedure timeline in Thailand is designed around patient safety, precise cellular administration, and rigorous acute monitoring. You cannot simply fly in, get an injection, and fly out on the same afternoon.

Day 1: Baseline Verification. Upon arrival in Bangkok, you undergo a comprehensive physical consultation. Specialists run updated blood panels, including CBC and infectious disease screens, to ensure no acute infections have developed during travel. You’ll consult directly with the attending hematologist or orthopedist to review imaging.

Day 2–3: Administration. Depending on the Regenerative Eligibility Matrix results, the cellular product is thawed from cryopreservation and prepared. Administration typically occurs via a slow intravenous (IV) drip for systemic conditions (taking about 45 to 60 minutes), or precise, ultrasound-guided localized injections for orthopedic issues. Patients are closely monitored in specialized recovery suites for any immediate adverse reactions.

Day 4–7: Monitoring and Adjunct Therapies. The medical team tracks vital signs and early physiological responses. Orthopedic patients may begin gentle, guided physical therapy. Many clinics incorporate adjunctive treatments like hyperbaric oxygen therapy (HBOT) or NAD+ IV drips to maximize cellular uptake. Once cleared by the attending physician, patients receive fit-to-fly certification and detailed post-care instructions.

Medical Limitations and Safety Precautions

Mesenchymal stem cell therapy Thailand offers is highly advanced, but acknowledging its limitations is the hallmark of responsible medicine. Any clinic failing to discuss potential failure rates is prioritizing sales over patient safety. Without objective biological boundaries, regenerative medicine quickly devolves into expensive guesswork.

Common Pitfalls in Cellular Therapy

The most frequent pitfall in regenerative medicine is the mismatch of expectations versus biology. Patients often arrive expecting a physical rebuilding of profoundly degraded anatomy. Here’s the truth if you have Grade IV osteoarthritis with complete cartilage loss and severe bone spurring, cellular therapy cannot physically rebuild that joint. Treating end-stage structural degeneration while expecting miraculous regeneration is a profound waste of resources.

Furthermore, patients often fall victim to aggressive marketing guaranteeing a “cure.” While allogeneic UC-MSCs are immunoprivileged, minor adverse reactions like low-grade fevers, transient fatigue, or localized injection-site swelling are common as the immune system initially interacts with the new paracrine signals.

Utilizing unverified laboratories that lack ISO cleanroom certification dramatically increases the risk of serious complications, including endotoxin shock or bacterial infection. If a clinic cannot

When to Seek Conventional Alternatives

Stem cell therapy is an incredibly powerful adjunct, but it is rarely a replacement for acute, conventional interventions. There are specific scenarios where cellular medicine is entirely contraindicated and standard allopathic care must take priority.

First, acute surgical emergencies require mechanical fixation. If you have a fully ruptured anterior cruciate ligament (ACL) or a severely displaced complex fracture, you need an orthopedic surgeon, not an IV drip. Stem cells cannot bridge massive mechanical gaps in destroyed tissue.

Second, patients with active, aggressive malignancies (cancer) are generally disqualified. Because stem cells secrete potent growth factors and promote aggressive angiogenesis (building new blood vessels), there is a theoretical risk that introducing these cells could inadvertently supply a tumor with the blood flow it needs to accelerate growth. In these instances, standard oncology protocols remain the absolute, undisputed priority.

Frequently Asked Questions

Are placenta stem cells better than umbilical cord stem cells?

Neither stem cell type is universally better; their efficacy depends entirely on the patient’s specific clinical diagnosis. Umbilical cord mesenchymal stem cells (UC-MSCs) are generally preferred for widespread immune modulation and treating autoimmune conditions. Conversely, placenta-derived stem cells possess superior angiogenic properties, making them highly effective for rapid vascular repair and targeted tissue regeneration. Medical specialists analyze a patient’s biological markers to determine the most appropriate cellular source. Individual outcomes rely on precise biological matching rather than a generic cellular superiority.

Is stem cell therapy in Thailand safe for international patients?

Stem cell therapy in Thailand is highly safe when administered by hospitals holding Joint Commission International (JCI) accreditation and adhering to strict Ministry of Public Health Over 140 officially registered clinical trials in the country demonstrate a robust adherence to global scientific safety standards. Patients must always independently verify a clinic’s medical credentials before proceeding.

How long does it take to see results from UC-MSC therapy?

Most patients observe initial biological improvements within 3 to 6 months following UC-MSC administration as paracrine signaling begins modulating systemic inflammation. Immediate relief in the first few weeks is occasionally reported, though this is often attributed to the rapid suppression of acute localized swelling rather than deep tissue repair. Long-term functional outcomes require cellular differentiation and extracellular matrix synthesis, which can take up to a year to fully mature. Results vary significantly based on the severity of the baseline condition, and continuous medical monitoring is required to accurately track physiological progress.

Conclusion

For patients seeking advanced regenerative medicine, placenta stem cell therapy in Thailand delivers highly regulated cellular interventions for chronic and autoimmune conditions. Clinical data indicates these therapies can modulate immune responses in up to 73% of refractory cases. The safest approach combines rigorous clinical vetting, transparent laboratory standards, and comprehensive post-treatment monitoring.

The core to achieving these outcomes relies entirely on The Regenerative Eligibility Matrix. Passing this objective assessment is the only way to ensure that the biological mechanisms of UC-MSCs and placental derivatives perfectly align with your exact diagnosis, separating true clinical potential from wasted medical travel.

If you are evaluating international regenerative medicine, your next step is data compilation. Schedule your preliminary clinical assessment today by submitting your recent medical imaging,